Evidence map›Paper›PMID 19630538›Full record

Trial reportJournal of women's health (2002)2009

Preferred characteristics of vaginal microbicides in women with bacterial vaginosis.

Robert L Cook, Julie S Downs, Jeanne Marrazzo, Galen E Switzer, Ozlem Tanriover, Harold Wiesenfeld, Pamela J Murray, Sharon L Hillier

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of women's health (2002), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. On-demand microbicide products: design matters.Drug delivery and translational research · 2017
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Robert L CookUniversity of Florida, Gainesville, FL 32610, USA. cookrl@phhp.ufl.edu
Julie S Downs
Jeanne Marrazzo
Galen E Switzer
Ozlem Tanriover
Harold Wiesenfeld
Pamela J Murray
Sharon L Hillier
Magee-Womens Hospital · USCarnegie Mellon University · USChildren's Hospital of Pittsburgh · USHarborview Medical Center · USUniversity of Florida · USUniversity of Pittsburgh · US

Funding

TRICHOMONAS VAGINALIS AND SLPI MUCOSAL DEFENSESU01AI047785 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L · 1999 to 2002
$1.8M
NIAID NIH HHS U01-AI-47785
6 · The paper itself

Abstract

backgroundVaginal microbicides have the potential to reduce HIV/STD acquisition when used consistently. Our objectives were to determine product attributes associated with willingness to use a vaginal microbicide and whether product preferences varied according to participant characteristics.

methodsWomen (n = 408) with bacterial vaginosis (BV) were recruited as part of a randomized trial to prevent BV. Participants completed a survey interview that assessed demographic information, sexual history, and douching behavior. To assess microbicide preferences, women rated whether specific product attributes would make them more or less likely to use a vaginal microbicide. Principal components analyses revealed two major groupings for the product attribute items. We determined the relative importance of each group of product attributes and whether the importance of the different groupings varied among subgroups of women.

resultsThe participants' mean age was 24 years (range 14-45), 64% were black, and 74% were unmarried. Overall, participants reported being most likely to use a vaginal product with protection properties (2.54), whereas they were nearly neutral regarding side effects (0.56). The individual product attributes, could prevent BV, could prevent vaginal odor (2.72), and could prevent vaginal itching and burning (2.61), were rated similarly or slightly higher than could reduce the risk of getting an STD (2.58) or could reduce the risk of getting HIV (2.44). In multivariate analyses, protection attributes were rated significantly higher among older women and marginally higher in women with a greater number of lifetime sexual partners. Younger women were most likely to report that side effects would affect their likelihood of using the product.

conclusionsWomen with BV rated potential protection features of a vaginal microbicide higher than side effects. A product's personal hygiene aspects were rated equally or more important than the product's ability to prevent HIV/STD infections. Younger women may respond to different factors that influence product acceptability and adherence.

Indexed as

Health Knowledge, Attitudes, PracticeAdolescentAdultAnti-Infective AgentsAttitude to HealthConsumer BehaviorFemaleHealth BehaviorHumansMiddle AgedPatient Acceptance of Health CareSelf CareSurveys and QuestionnairesUnited StatesVaginosis, BacterialWomen's HealthAnti-Infective Agents

Identifiers

PMID19630538
PMCPMC2825715
OpenAlexW2166156996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.